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Summary box
 ► Congenital Chagas disease (CCD) remains a public 
health problem in endemic countries.
 ► The current diagnostic algorithm based on sequen-
tial use of microscopy and serology misses a signif-
icant number of CCD cases.
 ► Robust, standardised and easier to implement 
molecular diagnostic methods for CCD are now 
available.
 ► Algorithms to diagnose CCD cases using molecular 
tools in endemic regions should be developed and 
implemented.
 ► Accurate and up-to-date data are needed on the 
number of infants screened and the number cases 
of CCD diagnosed.
AbSTrACT
It is estimated that between 8000 and 15 000 
Trypanosoma cruzi infected babies are born every 
year to infected mothers in Chagas disease endemic 
countries. Currently, poor access to and performance of 
the current diagnostic algorithm, based on microscopy 
at birth and serology at 8–12 months after delivery, is 
one of the barriers to congenital Chagas disease (CCD) 
control. Detection of parasite DNA using molecular 
diagnostic tools could be an alternative or complement 
to current diagnostic methods, but its implementation in 
endemic regions remains limited. Prompt diagnosis and 
treatment of CCD cases would have a positive clinical and 
epidemiological impact. In this paper, we analysed the 
burden of CCD in Latin America, and the potential use of 
molecular tests to improve access to early diagnosis and 
treatment of T. cruzi infected newborns.
InTroduCTIon
In 1998, Russomando et al concluded that 
‘the PCR has a clear advantage over conven-
tional techniques for the early detection of 
congenital transmission of Trypanosoma cruzi 
infection’.1 Twenty years later, in endemic 
countries, the use of molecular tools to diag-
nose infants infected with T. cruzi, the para-
site that causes Chagas disease by congenital 
transmission from infected mothers, is still 
limited. The arguments put forward to justify 
the limited use of molecular tools to diag-
nose congenital Chagas disease (CCD) in 
these countries are diverse, including: limited 
evidence that molecular tests perform better 
than standard procedures (eg, parasitology 
at birth and/or serology 8–12 months after 
birth), lack of standardisation, complexity 
and cost.
Diagnosing CCD should be a priority 
in endemic countries, as this has proven 
clinical and epidemiological benefits. In 
endemic countries such as Bolivia and Chile, 
controlling CCD is considered a cost-effec-
tive strategy2 3 as, in contrast to the disease in 
adults, the cure rate in infants less than 1 year 
old is almost 100% and tolerance to treatment 
is quite good.4 The cure rate decreases in 
older paediatric patients undergoing chronic 
infection.5 Treated and cured children would 
not develop cardiac and/or gastrointestinal 
forms of Chagas disease.6 Furthermore, if 
there is no reinfection later in life, treated 
girls will be significantly less likely to transmit 
the infection to their infants when they get 
older.7 Thus, the best diagnostic strategies for 
congenital Chagas should therefore be imple-
mented to ensure that cases are identified 
and treated promptly.
The 63rd World Health Assembly held in 
Geneva on 21 May 2010 urged governments 
to ‘establish systems of early detection, in 
particular for the detection of new infec-
tions, congenital infections in newborns ’.8 
In endemic countries, the current strategy to 
diagnose and treat CCD is based on a series of 
steps which leave much to be desired. First, T. 
cruzi-infected mothers should be identified by 
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serological analysis. Children born to an infected mother 
should then be tested either by microscopy shortly after 
birth and/or serology 8–12 months after birth. Children 
who are positive by microscopy (parasites observed in 
capillary or umbilical cord blood) and/or serology are 
considered to be CCD cases and are treated.9 Serological 
tests cannot be used to diagnose T. cruzi infection in babies 
soon after they are born as maternal antibodies could 
cause false positive results. While algorithms for diag-
nosis of CCD vary from country to country, they adhere 
to the general multistep process, which has well-reported 
limitations, in particular the low sensitivity of microscopy 
and the loss to follow-up at 8–12 months.10 11 A number 
of studies have corroborated the results of Russomando 
et al and have shown that molecular tools performed 1 
month after birth, in place of microscopy, outperform 
the current diagnostic algorithm.10–16 However, despite 
their availability, molecular tests are rarely used to diag-
nose CCD. To our knowledge, Chile is the only endemic 
country that routinely uses PCR as part of a national 
strategy,17 while Argentina is scaling up its use. In the 
rest of Latin America, PCR is sometimes mentioned in 
the guidelines as a potential diagnostic tool but is not 
included in diagnostic algorithms.18 19 In contrast, PCR is 
part of the diagnostic algorithm for CCD in non-endemic 
high-income countries, such as Spain20 and Switzerland.21
In this paper, we demonstrate that CCD remains a 
public health problem in Latin America by estimating 
the burden of disease, the number of children born to 
T. cruzi infected mothers who should be screened so they 
can be treated if required and the number of CCD cases 
missed by the current diagnostic strategy. We have also 
analysed the limitations and arguments that preclude 
implementation of molecular tests to diagnose CCD in 
those countries and suggest ways to overcome them.
burden of CCd And number of newbornS THAT SHould 
be TeSTed for THe dISeASe
The WHO estimates that in 2010, there were 8668 new 
cases of CCD in Latin American countries.22 These CCD 
cases represented 22% (8668/38 593) of all new cases of 
Chagas disease that year.22 The weight that congenital 
transmission has in the burden of Chagas disease will 
continue to increase in significance, as other modes of 
transmission (eg, vector and blood-transfusion) are being 
controlled. Transmission of Chagas disease through 
blood transfusion was interrupted in most Latin Amer-
ican countries (20 out of 21) by 201523 and vectorial trans-
mission has been interrupted in a number of endemic 
countries and regions.8 Congenital infection of T. cruzi 
is now the first cause of new cases of Chagas disease in 
Argentina.24 The number of CCD cases is used to estimate 
the burden of congenital transmission; however, there is 
another key parameter that should be considered when 
planning and assessing CCD control programmes: the 
number of babies that should be tested. The number of 
children born to infected mothers is significantly larger 
than the number of CCD cases as the transmission rate 
of T. cruzi from mother to child is around 5% (95% CI 
4% to 6%) in endemic countries.25 As it happens with the 
chronic form of Chagas disease, epidemiological data on 
CCD are scarce. There are no estimates on the number 
of children born to T. cruzi-infected mothers in endemic 
countries who should have been tested at birth.
In this paper, we have adapted the model developed 
by WHO to estimate the burden of Chagas disease in 
Latin America in 201022 26 to estimate the number of 
babies born to T. cruzi-infected mothers in the region in 
2010. First, we derived demographic data from the WHO 
report,22 which was based on 2010 national censuses, 
whenever these data were available. For those countries 
without data in the WHO report, population projec-
tions were obtained from the United Nations and the 
Economic Commission for Latin America and the Carib-
bean. Population tables on women of childbearing age 
(15–44 years of age) were obtained from the U.S. Census 
Bureau International Data Base, while annual numbers 
of births by country were extracted from PAHO/WHO 
Basic Indicators 2010. We used the T. cruzi infection prev-
alence ranges reported per country22 27 28 to calculate the 
total population infected and the number of infected 
women of childbearing age. Finally, we derived birth rates 
per country—adjusting the rates by a factor of 1.5 due to 
higher birth rates in rural areas22—of infected women of 
childbearing age, in order to develop a range estimate of 
the number of babies born to infected mothers.
The number of babies that would need to be tested per 
year varies from 157 972 to 214 074, depending on the 
estimate of the prevalence of T. cruzi infection (table 1). 
Argentina, Brazil, Bolivia and Mexico are the countries 
where most tests should be conducted (figure 1). Taking 
5% as the average T. cruzi transmission rate from infected 
mothers to newborns,25 the annual prevalence of CCD 
cases in Latin America in 2010 ranged from 7899 to 10 
704. These numbers are similar to those estimated by 
WHO in previous reports: 15 000 in 2006 and 8700 in 
2010.22 28 Our estimates can be used as a reference but 
some limitations in the calculations should be consid-
ered: for example, the performance of serological tests 
and the congenital transmission rate vary among coun-
tries.26 Accurate and up-to-date data are needed in 
endemic countries.
SenSITIvITy of THe CongenITAl CHAgAS dISeASe 
dIAgnoSTIC AlgorITHm
There are no accurate records on the number of 
infants born to infected mothers that are actually 
tested in endemic countries. Such data would be useful 
in estimating the coverage achieved by CCD control 
programmes and the likely number of cases missed. 
Sensitivity, defined as the number of Chagas disease cases 
correctly identified by the diagnostic algorithm, depends 
on (1) the characteristics of the tests used (eg, sensitivity 
of microscopy and serology) and (2) the capacity of the 
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Figure 1 Estimated number of infants born to T. cruzi-infected mothers who should have been tested for congenital Chagas 
disease in 2010 in Latin American countries. The minimum and maximum number of babies that would need to be tested per 
country are presented. The estimates are presented in detail in table 1.
Table 2 Number of pregnant women screened, babies tested and CCD cases identified by Bolivia’s national control 
programme in 2009, and the estimated number of CCD cases missed due to inadequate coverage
Variable Estimates Source
Pregnant women
# of pregnant women screened 112 160 Tables 5–829
# of pregnant women who are also seropositive 24 748 Tables 5–829
Seroprevalence in pregnant women 22% Calculated: 24 748/112 160
Babies born to infected mothers
# of babies tested 16 185 Tables 5–829
# of babies not tested (assuming one baby per pregnancy) 8563 Calculated: 24 748–16 185
% babies tested following the diagnostic algorithm 65% Calculated: 16 185/24 748
Congenital Chagas disease (CCD) cases
# CCD cases identified 329 Tables 5–829
Rate of congenital transmission 2% Calculated: 329/16 185
# of CCD cases missed because babies were not tested 174 Calculated: 2%x8563
CCD, congenital Chagas disease.
health system to screen mothers and newborns when 
required, including the follow-up of babies 8–12 months 
after birth.
We used the number of pregnant women screened, 
their seroprevalence, the number of babies tested and 
the number of CCD cases identified in Bolivia in 2009, as 
reported by Alonso-Vega et al,29 to estimate the number 
of CCD cases missed by the national control programme 
(NCP) that year. The calculations summarised in table 2 
indicate that 174 patients with CCD would have been 
missed, as the programme is unable to test all the babies 
born to T. cruzi-infected mothers. This estimate assumes 
that all pregnant women at risk in Bolivia were screened 
(319 014 pregnancies estimated in Bolivia in 2009), 
using a test with a sensitivity of 100%, and the diagnostic 
algorithm for babies (microscopy and serology) was also 
100% sensitive. Had the sensitivity of the algorithm been 
reduced to 80% (ie, loss to follow-up of babies tested by 
microscopy but not by serology at 8–12 months), then 
the total number of CCD cases in Bolivia in 2009 would 
have been 629 and only 52% (n=329) would have been 
identified by the NCP.
This case study illustrates the limitations of the current 
diagnostic tools and the health system in identifying all 
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CCD cases in Bolivia, which may be similar to the situa-
tion in other Latin American countries.
ImplemenTATIon of moleCulAr ToolS To TeST for 
CongenITAl CHAgAS dISeASe
Development of point-of-care (PoC) tests to diagnose 
CCD remains a priority30 31 and some biomarkers have 
shown promising results.32 33 Until these PoC tests are 
developed, molecular tools for detection of parasite 
DNA remain the best alternatives to complement current 
methods. A number of reasons for the limited imple-
mentation of molecular tools in the diagnosis of CCD in 
endemic countries have been identified. We review the 
most relevant here.
lack of clinical evidence
PCR has been shown to have a higher sensitivity for para-
site detection than other conventional methods such as 
microscopy, hemoculture or xenodiagnosis.1 10 16 34 It is 
also superior to conventional methods in the diagnosis 
and follow-up of infected newborns. Up to 100% sensi-
tivity has been reported in the detection of T. cruzi in 
neonates within the first 3 months of age, which quali-
fies PCR for early-stage diagnosis of CCD.24 35–37 However, 
PCR may not be ideal in cases of CCD without persistent 
parasitaemia, and as a result, sampling at different time 
points from birth may be needed.38 A cohort study in 
an endemic setting in Bolivia that included PCR in the 
algorithm for detecting vertical transmission of Chagas 
disease demonstrated its superiority over serology and 
microscopy.14
lack of standardisation
There are a number of factors affecting the diagnostic 
performance of PCR that could be a hindrance to stand-
ardisation across settings where the use of home-brewed 
PCR methods is the rule. From the source, volume and 
timing of clinical sampling to more technical issues 
such as the use of anticoagulants and/or stabilising 
agents, the method used to purify DNA, the target DNA 
sequence, primers and probes design, the chemistry 
used in the reaction and the platform in which the test 
is performed.39 There is evidence that blood sampling at 
1 month after birth improves accuracy of molecular diag-
nosis.26 40 And there have been successful examples of 
validating and harmonising home-brewed or commercial 
PCR and real-time quantitative PCR methods.41 42 Both 
efforts will hopefully contribute to implement a strategy 
for a timely and effective diagnosis of CCD.
Complexity
Real-time PCR kits for detection of T. cruzi are commer-
cially available such as RealCycler CHAG (Progenie, 
Spain) or TCRUZIDNA.CE (Diagnostics Bioprobes Srl, 
Italy) but their implementation in low-resource settings 
is limited due to their cost and the need for cold chain 
for transport and storage. Thus, the lack of robust, field 
amenable and ready-to-use PCR formats has limited 
its use to reference laboratories. A method that could 
overcome these hurdles is loop-mediated isothermal 
amplification (LAMP) of DNA. This test is performed at 
constant temperature (60°C–65°C), enabling amplifica-
tion with high efficiency, in a short time. A thermocy-
cler is not required but a simpler device that allows for 
isothermal incubation such as a thermal block. Results 
are easily visualised using simple detection methods.43 
An advantage of LAMP is that it uses multiple primers 
targeting different regions of the target DNA, which 
makes it highly sensitive and specific. Recently, the analyt-
ical sensitivity and specificity of a LAMP kit developed 
by Eiken Chemical Co. (Japan, Loopamp Trypanosoma 
cruzi Detection Kit) on clinical samples from CCD cases 
were shown to be similar to those of PCR in Argentina.44 
The simplicity of its format, with reagents dried down in 
reaction tubes that can be stored at room temperature, 
enables its use for the diagnosis of CCD in resource-lim-
ited settings.44 Other groups have developed similar 
LAMP kits to detect T. cruzi DNA.45 Another platform 
that meets the criteria for implementation of molecular 
diagnosis at such sites is recombinase polymerase ampli-
fication (RPA), which also enables sensitive, specific and 
rapid amplification of DNA under isothermal condi-
tions. The RPA reaction runs optimally at 37°C–42°C 
which may present an advantage in terms of energy costs 
saving. This test can also be produced in dry format and 
has shown great potential in the diagnosis of infections 
by protozoan parasites.46 A prototype RPA test coupled 
with lateral flow assay for product detection has been 
used to identify T. cruzi infection in dogs, showing similar 
performance to qPCR.47
Cost and implementation
While molecular tests may be more expensive than 
serology or microscopy, their superior diagnostic perfor-
mance would enable the detection and treatment of a 
higher number of cases. The high efficacy of treatment 
of CCD may provide an opportunity to demonstrate that 
molecular tests are cost-effective, as shown in Chile.3 
Testing for different pathogens using the same plat-
form would reduce costs related to implementation of 
molecular diagnostics in resource-limited settings. For 
example, the Loopamp platform by Eiken Chemical Co. 
has been used to develop LAMP tests for the diagnosis of 
Chagas disease, leishmaniasis, malaria and tuberculosis, 
the latter endorsed by WHO.48–50 As these diseases are 
coendemic in various geographic regions, health systems 
have the possibility of using this platform to test for 
multiple pathogens.
The barriers to implementing these technologies in 
resource-limited settings may have less to do with their 
complexity and more with the fact that they require the 
engagement and commitment of different stakeholders 
to align the necessary resources.51
ConCluSIon
It is 20 years since Russomando et al made their state-
ment about the superiority of PCR over conventional 
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techniques and yet molecular tools to diagnose CCD 
in endemic countries have still not been broadly imple-
mented. These tools may not be perfect38 but undoubt-
edly have a role to play in CCD control programmes, 
particularly if we take advantage of recently developed 
technologies. Improved access to prompt and accurate 
diagnosis for babies at risk of T. cruzi infection should 
be integrated with other interventions: vector control to 
avoid reinfection, treatment of women of childbearing 
age to prevent congenital transmission,7 interruption of 
mother-to-child transmission of HIV and syphilis52 and 
screening of congenital disorders in newborns using 
dried blood spots.53 Delaying the implementation of 
more efficient diagnostic algorithms sentences a signifi-
cant number of children to the risk of developing Chagas 
disease and transmitting T. cruzi parasites to the next 
generation.
recommendations
 ► Estimate the number of infants born to T. cruzi-in-
fected mothers, and the number of newborns tested 
in endemic countries per year. These indicators 
should be used to monitor coverage of CCD control 
programmes.54
 ► Develop target product profiles to define the tech-
nical requirements of point-of-care diagnostic tools 
(molecular and others) for CCD30 55 and support the 
development and implementation of novel tools to 
diagnose CCD.
 ► Establish sample banks of CCD cases and controls 
to allow a rapid and standardised evaluation of new 
tools (molecular or others) to diagnose congenital 
transmission of T. cruzi. These sample banks should 
be representative of the different endemic areas and 
should include different sample types (eg, blood and 
urine).
 ► Develop and evaluate algorithms to diagnose CCD 
using molecular tools based on the evidence and 
experience of control programmes that are currently 
employing these tools.
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